NASDAQ:QTNT - Quotient Stock Price, Forecast & News

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient Ltd (NASDAQ:QTNT) released its quarterly earnings results on Thursday, January, 30th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The firm had revenue of $7.94 million for the quarter, compared to the consensus estimate of $7.10 million. View Quotient's Earnings History.

Quotient is scheduled to release their next quarterly earnings announcement on Tuesday, May 26th 2020. View Earnings Estimates for Quotient.

1 equities research analysts have issued 1 year target prices for Quotient's stock. Their forecasts range from $13.50 to $13.50. On average, they expect Quotient's stock price to reach $13.50 in the next year. This suggests a possible upside of 91.2% from the stock's current price. View Analyst Price Targets for Quotient.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.

Media headlines about QTNT stock have trended negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a news impact score of -2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Quotient.

Some companies that are related to Quotient include Myriad Genetics (MYGN), Heska (HSKA), Intellia Therapeutics (NTLA), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), Pieris Pharmaceuticals (PIRS), Zynerba Pharmaceuticals (ZYNE) and Abeona Therapeutics (ABEO).

Quotient's stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (16.55%), Farallon Capital Management LLC (3.11%), Credit Suisse AG (3.04%), FMR LLC (2.51%), Broadfin Capital LLC (2.48%) and Artisan Partners Limited Partnership (1.57%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Prondzynski Heino Von and Roland Boyd. View Institutional Ownership Trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Marshall Wace North America L.P., Goldman Sachs Group Inc., Cubist Systematic Strategies LLC and FNY Investment Advisers LLC. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz and Roland Boyd. View Insider Buying and Selling for Quotient.

QTNT stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Broadfin Capital LLC, Farallon Capital Management LLC, Credit Suisse AG, Artisan Partners Limited Partnership, Castleark Management LLC, Sei Investments Co. and Marshall Wace LLP. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QTNT stock can currently be purchased for approximately $7.06.

Quotient has a market capitalization of $566.99 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.

The official website for Quotient is http://www.quotientbd.com/.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.